The following news release is from Neuronetics.

Edited by Infolytica Corporation on August 14th, 2006.

Neuronetics, Inc., a privately held medical device company and developer of the NeuroStar TMS Therapy System™ for the treatment of major depression, recently announced results of the first multicenter, controlled clinical trial for transcranial magnetic stimulation (TMS) therapy. The study demonstrated that TMS Therapy™ is an effective, safe, well tolerated antidepressant for patients who have not received adequate benefit from previous antidepressant medications. The trial results were presented at the American Psychiatric Association Meeting in Toronto, Canada.

NeuroStar TMS Therapy™, which is currently under review by the FDA and is pending market clearance for the treatment of major depression, is a non-invasive, outpatient treatment. It uses highly focused, pulsed magnetic fields to stimulate nerve cells in brain regions believed to be linked to depression. TMS Therapy does not require anesthesia or sedation, so patients can resume normal activities immediately after the 40-minute treatment.

The randomized, sham-controlled clinical trial was conducted at 23 leading clinical research institutions throughout the U.S., Canada and Australia to test the acute efficacy and safety of NeuroStar TMS Therapy. Extension studies provided open-label treatment for non-responders and a 6-month observation period for maintenance of response. All 301 patients who participated were suffering from major depression and had not benefited from previous antidepressant medication therapy.

"TMS Therapy offers patients with resistant depression a non-invasive, drug-free treatment alternative. In the randomized, controlled trial, TMS-treated patients had significantly higher response and remission rates than sham-treated patients," said psychiatrist John O'Reardon, M.D., Director of the University of Pennsylvania's Treatment Resistant Depression Clinic and a principal investigator of the trial. "Additionally, TMS Therapy was remarkably well tolerated with less than 8% of patients leaving the study during the acute treatment trial. It clearly provides new hope for depressed patients."

Read the rest of this press release at http://www.neuronetics.com/scientificdata.html

About Neuronetics, Inc.

Neuronetics, Inc. is a privately held medical device company focused on developing therapies for psychiatric and neurological disorders using the energy in magnetic fields. Based in Malvern, PA., Neuronetics is the leader in the development of TMS Therapy, a completely non-invasive form of neuromodulation. For more information, visit www.neuronetics.com.